Which has higher valuation & earnings, NAGE or XNCR?

Niagen Bioscience has higher revenue and earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Niagen Bioscience $129.42M 1.98 $17.38M $0.21 15.29 Xencor $125.58M 11.48 -$91.92M -$2.29 N/A

Is NAGE or XNCR more profitable?

Niagen Bioscience has a net margin of 14.29% compared to Xencor's net margin of -177.10%. Niagen Bioscience's return on equity of 22.68% beat Xencor's return on equity. Company Net Margins Return on Equity Return on Assets Niagen Bioscience 14.29% 22.68% 16.23% Xencor -177.10% -28.77% -20.52%

Does the media favor NAGE or XNCR?

In the previous week, Xencor had 3 more articles in the media than Niagen Bioscience. MarketBeat recorded 5 mentions for Xencor and 2 mentions for Niagen Bioscience. Niagen Bioscience's average media sentiment score of 1.26 beat Xencor's score of 0.53 indicating that Niagen Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Niagen Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xencor 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor WVE or NAGE?

In the previous week, WAVE Life Sciences had 6 more articles in the media than Niagen Bioscience. MarketBeat recorded 8 mentions for WAVE Life Sciences and 2 mentions for Niagen Bioscience. Niagen Bioscience's average media sentiment score of 1.26 beat WAVE Life Sciences' score of 0.82 indicating that Niagen Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Niagen Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NAGE or CRON?

In the previous week, Cronos Group had 4 more articles in the media than Niagen Bioscience. MarketBeat recorded 6 mentions for Cronos Group and 2 mentions for Niagen Bioscience. Niagen Bioscience's average media sentiment score of 1.26 beat Cronos Group's score of 0.76 indicating that Niagen Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Niagen Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cronos Group 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CVAC or NAGE?

Niagen Bioscience has a consensus price target of $10.50, indicating a potential upside of 227.10%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Niagen Bioscience is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Niagen Bioscience 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00

Does the media favor NAGE or ETON?

In the previous week, Eton Pharmaceuticals had 4 more articles in the media than Niagen Bioscience. MarketBeat recorded 6 mentions for Eton Pharmaceuticals and 2 mentions for Niagen Bioscience. Niagen Bioscience's average media sentiment score of 1.26 beat Eton Pharmaceuticals' score of 0.93 indicating that Niagen Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Niagen Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eton Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Niagen Bioscience (NAGE) Competitors

$3.21 +0.02 (+0.63%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$3.22 +0.00 (+0.16%)

As of 07/24/2026 07:34 PM Eastern

Compare

NAGE vs. XNCR, WVE, CRON, CVAC, and ETON

Should you buy Niagen Bioscience stock or one of its competitors? MarketBeat compares Niagen Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Niagen Bioscience include Xencor (XNCR), WAVE Life Sciences (WVE), Cronos Group (CRON), CureVac (CVAC), and Eton Pharmaceuticals (ETON). These companies are all part of the "pharmaceutical products" industry.

How does Niagen Bioscience compare to Xencor?

Niagen Bioscience (NASDAQ:NAGE) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

Niagen Bioscience has a net margin of 14.29% compared to Xencor's net margin of -177.10%. Niagen Bioscience's return on equity of 22.68% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	14.29%	22.68%	16.23%
Xencor	-177.10%	-28.77%	-20.52%

Niagen Bioscience currently has a consensus price target of $10.50, indicating a potential upside of 227.10%. Xencor has a consensus price target of $24.25, indicating a potential upside of 24.74%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Niagen Bioscience is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Niagen Bioscience has higher revenue and earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$129.42M	1.98	$17.38M	$0.21	15.29
Xencor	$125.58M	11.48	-$91.92M	-$2.29	N/A

Niagen Bioscience has a beta of 2.09, meaning that its share price is 109% more volatile than the broader market. Comparatively, Xencor has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

In the previous week, Xencor had 3 more articles in the media than Niagen Bioscience. MarketBeat recorded 5 mentions for Xencor and 2 mentions for Niagen Bioscience. Niagen Bioscience's average media sentiment score of 1.26 beat Xencor's score of 0.53 indicating that Niagen Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Niagen Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xencor	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.4% of Niagen Bioscience shares are owned by institutional investors. 10.0% of Niagen Bioscience shares are owned by insiders. Comparatively, 5.1% of Xencor shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Niagen Bioscience beats Xencor on 14 of the 17 factors compared between the two stocks.

How does Niagen Bioscience compare to WAVE Life Sciences?

WAVE Life Sciences (NASDAQ:WVE) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 24.3% of WAVE Life Sciences shares are held by company insiders. Comparatively, 10.0% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Niagen Bioscience has a net margin of 14.29% compared to WAVE Life Sciences' net margin of -255.70%. Niagen Bioscience's return on equity of 22.68% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-255.70%	-56.76%	-42.80%
Niagen Bioscience	14.29%	22.68%	16.23%

WAVE Life Sciences presently has a consensus target price of $26.41, indicating a potential upside of 354.59%. Niagen Bioscience has a consensus target price of $10.50, indicating a potential upside of 227.10%. Given WAVE Life Sciences' higher probable upside, analysts clearly believe WAVE Life Sciences is more favorable than Niagen Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00

Niagen Bioscience has higher revenue and earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	26.16	-$204.38M	-$1.06	N/A
Niagen Bioscience	$129.42M	1.98	$17.38M	$0.21	15.29

WAVE Life Sciences has a beta of -1.29, indicating that its stock price is 229% less volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.09, indicating that its stock price is 109% more volatile than the broader market.

In the previous week, WAVE Life Sciences had 6 more articles in the media than Niagen Bioscience. MarketBeat recorded 8 mentions for WAVE Life Sciences and 2 mentions for Niagen Bioscience. Niagen Bioscience's average media sentiment score of 1.26 beat WAVE Life Sciences' score of 0.82 indicating that Niagen Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Niagen Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Niagen Bioscience beats WAVE Life Sciences on 10 of the 16 factors compared between the two stocks.

How does Niagen Bioscience compare to Cronos Group?

Niagen Bioscience (NASDAQ:NAGE) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Niagen Bioscience has higher earnings, but lower revenue than Cronos Group. Niagen Bioscience is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$129.42M	1.98	$17.38M	$0.21	15.29
Cronos Group	$159.54M	6.57	-$9.45M	$0.01	281.00

In the previous week, Cronos Group had 4 more articles in the media than Niagen Bioscience. MarketBeat recorded 6 mentions for Cronos Group and 2 mentions for Niagen Bioscience. Niagen Bioscience's average media sentiment score of 1.26 beat Cronos Group's score of 0.76 indicating that Niagen Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Niagen Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cronos Group	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Niagen Bioscience has a beta of 2.09, indicating that its stock price is 109% more volatile than the broader market. Comparatively, Cronos Group has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

Niagen Bioscience currently has a consensus price target of $10.50, suggesting a potential upside of 227.10%. Cronos Group has a consensus price target of $2.30, suggesting a potential downside of 18.15%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, equities research analysts plainly believe Niagen Bioscience is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00
Cronos Group	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Niagen Bioscience has a net margin of 14.29% compared to Cronos Group's net margin of -1.14%. Niagen Bioscience's return on equity of 22.68% beat Cronos Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	14.29%	22.68%	16.23%
Cronos Group	-1.14%	-1.26%	-1.20%

15.4% of Niagen Bioscience shares are held by institutional investors. Comparatively, 8.7% of Cronos Group shares are held by institutional investors. 10.0% of Niagen Bioscience shares are held by company insiders. Comparatively, 7.8% of Cronos Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Niagen Bioscience beats Cronos Group on 12 of the 16 factors compared between the two stocks.

How does Niagen Bioscience compare to CureVac?

CureVac (NASDAQ:CVAC) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

CureVac has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.09, suggesting that its stock price is 109% more volatile than the broader market.

In the previous week, Niagen Bioscience had 2 more articles in the media than CureVac. MarketBeat recorded 2 mentions for Niagen Bioscience and 0 mentions for CureVac. Niagen Bioscience's average media sentiment score of 1.26 beat CureVac's score of 0.00 indicating that Niagen Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
Niagen Bioscience	Positive

17.3% of CureVac shares are owned by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are owned by institutional investors. 2.2% of CureVac shares are owned by insiders. Comparatively, 10.0% of Niagen Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Niagen Bioscience has a consensus price target of $10.50, indicating a potential upside of 227.10%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Niagen Bioscience is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00

CureVac has higher earnings, but lower revenue than Niagen Bioscience. CureVac is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Niagen Bioscience	$129.42M	1.98	$17.38M	$0.21	15.29

CureVac has a net margin of 199.92% compared to Niagen Bioscience's net margin of 14.29%. Niagen Bioscience's return on equity of 22.68% beat CureVac's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Niagen Bioscience	14.29%	22.68%	16.23%

Summary

Niagen Bioscience beats CureVac on 12 of the 17 factors compared between the two stocks.

How does Niagen Bioscience compare to Eton Pharmaceuticals?

Niagen Bioscience (NASDAQ:NAGE) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

Niagen Bioscience has a beta of 2.09, suggesting that its stock price is 109% more volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market.

Niagen Bioscience presently has a consensus target price of $10.50, suggesting a potential upside of 227.10%. Eton Pharmaceuticals has a consensus target price of $45.75, suggesting a potential upside of 7.42%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, research analysts clearly believe Niagen Bioscience is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00
Eton Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Eton Pharmaceuticals had 4 more articles in the media than Niagen Bioscience. MarketBeat recorded 6 mentions for Eton Pharmaceuticals and 2 mentions for Niagen Bioscience. Niagen Bioscience's average media sentiment score of 1.26 beat Eton Pharmaceuticals' score of 0.93 indicating that Niagen Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Niagen Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eton Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Niagen Bioscience has higher revenue and earnings than Eton Pharmaceuticals. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$129.42M	1.98	$17.38M	$0.21	15.29
Eton Pharmaceuticals	$79.95M	14.59	-$4.60M	-$0.07	N/A

15.4% of Niagen Bioscience shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 10.0% of Niagen Bioscience shares are held by company insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Niagen Bioscience has a net margin of 14.29% compared to Eton Pharmaceuticals' net margin of -1.70%. Niagen Bioscience's return on equity of 22.68% beat Eton Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	14.29%	22.68%	16.23%
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%

Summary

Niagen Bioscience beats Eton Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Niagen Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NAGE vs. The Competition

Export

Metric	Niagen Bioscience	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$254.07M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	15.29	21.29	27.11	23.64
Price / Sales	1.98	170.12	517.09	89.57
Price / Cash	15.73	157.90	50.54	59.64
Price / Book	3.34	7.88	10.28	6.07
Net Income	$17.38M	$23.86M	$3.60B	$331.99M
7 Day Performance	-2.13%	-3.82%	-1.27%	-0.63%
1 Month Performance	-3.02%	-2.61%	-0.37%	-2.00%
1 Year Performance	-65.56%	32.79%	18.30%	13.62%

Niagen Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NAGE Niagen Bioscience	4.257 of 5 stars	$3.21 +0.6%	$10.50 +227.1%	-65.4%	$254.07M	$129.42M	15.29	120	Positive News
XNCR Xencor	2.6358 of 5 stars	$14.68 -2.0%	$24.25 +65.2%	+110.4%	$1.09B	$125.58M	N/A	280
WVE WAVE Life Sciences	3.465 of 5 stars	$5.64 -4.7%	$26.41 +368.7%	-30.8%	$1.09B	$42.73M	N/A	240	News Coverage Upcoming Earnings Analyst Upgrade
CRON Cronos Group	1.0936 of 5 stars	$2.80 +2.0%	$2.30 -17.7%	+35.7%	$1.05B	$146.59M	280.78	450	News Coverage
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NAGE) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Niagen Bioscience (NAGE) Competitors

NAGE vs. XNCR, WVE, CRON, CVAC, and ETON

How does Niagen Bioscience compare to Xencor?

Summary

How does Niagen Bioscience compare to WAVE Life Sciences?

Summary

How does Niagen Bioscience compare to Cronos Group?

Summary

How does Niagen Bioscience compare to CureVac?

Summary

How does Niagen Bioscience compare to Eton Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAGE vs. The Competition

Niagen Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Niagen Bioscience (NAGE) Competitors

NAGE vs. XNCR, WVE, CRON, CVAC, and ETON

How does Niagen Bioscience compare to Xencor?

Is NAGE or XNCR more profitable?

Do analysts recommend NAGE or XNCR?

Which has higher valuation & earnings, NAGE or XNCR?

Which has more volatility and risk, NAGE or XNCR?

Does the media favor NAGE or XNCR?

Do insiders & institutionals believe in NAGE or XNCR?

Summary

How does Niagen Bioscience compare to WAVE Life Sciences?

Do insiders and institutionals believe in WVE or NAGE?

Is WVE or NAGE more profitable?

Do analysts prefer WVE or NAGE?

Which has preferable earnings & valuation, WVE or NAGE?

Which has more volatility and risk, WVE or NAGE?

Does the media favor WVE or NAGE?

Summary

How does Niagen Bioscience compare to Cronos Group?

Which has better earnings and valuation, NAGE or CRON?

Does the media refer more to NAGE or CRON?

Which has more risk and volatility, NAGE or CRON?

Do analysts recommend NAGE or CRON?

Is NAGE or CRON more profitable?

Do insiders & institutionals hold more shares of NAGE or CRON?

Summary

How does Niagen Bioscience compare to CureVac?

Which has more risk & volatility, CVAC or NAGE?

Does the media prefer CVAC or NAGE?

Do insiders and institutionals have more ownership in CVAC or NAGE?

Do analysts recommend CVAC or NAGE?

Which has better earnings and valuation, CVAC or NAGE?

Is CVAC or NAGE more profitable?

Summary

How does Niagen Bioscience compare to Eton Pharmaceuticals?

Which has more volatility and risk, NAGE or ETON?

Do analysts rate NAGE or ETON?

Does the media favor NAGE or ETON?

Which has preferable earnings and valuation, NAGE or ETON?

Do insiders & institutionals have more ownership in NAGE or ETON?

Is NAGE or ETON more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAGE vs. The Competition

Niagen Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools